Hanley MJ - Search Results

1

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer.

Gupta N, Pierrillas PB, Hanley MJ, Zhang S, Diderichsen PM. Gupta N, et al. Among authors: hanley mj. CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):731-744. doi: 10.1002/psp4.12785. Epub 2022 Apr 11. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35316867 Free PMC article. Clinical Trial.

2

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.

Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ. Gupta N, et al. Among authors: hanley mj. J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1. J Hematol Oncol. 2015. PMID: 26337806 Free PMC article. Clinical Trial.

3

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Gupta N, Hanley MJ, Venkatakrishnan K, Wang B, Sharma S, Bessudo A, Hui AM, Nemunaitis J. Gupta N, et al. Among authors: hanley mj. J Clin Pharmacol. 2016 Oct;56(10):1288-95. doi: 10.1002/jcph.719. Epub 2016 Mar 17. J Clin Pharmacol. 2016. PMID: 26872892 Free PMC article. Clinical Trial.

4

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.

Gupta N, Hanley MJ, Venkatakrishnan K, Perez R, Norris RE, Nemunaitis J, Yang H, Qian MG, Falchook G, Labotka R, Fu S. Gupta N, et al. Among authors: hanley mj. Br J Clin Pharmacol. 2016 Sep;82(3):728-38. doi: 10.1111/bcp.12991. Epub 2016 May 29. Br J Clin Pharmacol. 2016. PMID: 27121262 Free PMC article. Clinical Trial.

5

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.

Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A. Gupta N, et al. Among authors: hanley mj. Br J Haematol. 2016 Sep;174(5):748-59. doi: 10.1111/bjh.14125. Epub 2016 May 16. Br J Haematol. 2016. PMID: 27196567 Free PMC article. Clinical Trial.

6

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K. Gupta N, et al. Among authors: hanley mj. Clin Pharmacokinet. 2017 Nov;56(11):1355-1368. doi: 10.1007/s40262-017-0526-4. Clin Pharmacokinet. 2017. PMID: 28290121 Free PMC article.

7

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range.

Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, Esseltine DL, Horton TM, Aplenc R, Alonzo TA, Lu X, Milton A, Venkatakrishnan K. Hanley MJ, et al. J Clin Pharmacol. 2017 Sep;57(9):1183-1193. doi: 10.1002/jcph.906. Epub 2017 Apr 18. J Clin Pharmacol. 2017. PMID: 28419486 Free PMC article. Clinical Trial.

8

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Hanley MJ, Gupta N, Venkatakrishnan K, Bessudo A, Sharma S, O'Neil BH, Wang B, van de Velde H, Nemunaitis J. Hanley MJ, et al. J Clin Pharmacol. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Epub 2017 Aug 7. J Clin Pharmacol. 2018. PMID: 28783865 Clinical Trial.

9

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.

Gupta N, Hanley MJ, Venkatakrishnan K, Bessudo A, Rasco DW, Sharma S, O'Neil BH, Wang B, Liu G, Ke A, Patel C, Rowland Yeo K, Xia C, Zhang X, Esseltine DL, Nemunaitis J. Gupta N, et al. Among authors: hanley mj. J Clin Pharmacol. 2018 Feb;58(2):180-192. doi: 10.1002/jcph.988. Epub 2017 Aug 11. J Clin Pharmacol. 2018. PMID: 28800141 Free PMC article. Clinical Trial.

10

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.

Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T, Venkatakrishnan K. Gupta N, et al. Among authors: hanley mj. Target Oncol. 2017 Oct;12(5):643-654. doi: 10.1007/s11523-017-0524-3. Target Oncol. 2017. PMID: 28803351 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters